Journal Article Summary
The article explores the complex role of neurotransmitter dysregulation in Parkinson's disease (PD), a common neurodegenerative disorder characterized by motor symptoms such as bradykinesia, rigidity, and tremors. Understanding the involvement of various neurotransmitter systems is crucial because current treatments primarily focus on dopamine (DA) replacement, which does not address the broader neurochemical imbalances that contribute to the disease's progression and symptom variability. By examining the interactions between different neurotransmitters, the authors aim to highlight potential new therapeutic strategies that could improve patient outcomes.
The review summarizes recent findings on the contributions of several neurotransmitter systems, including dopaminergic, glutamatergic, GABAergic, and serotonergic pathways, to the pathophysiology of PD. The authors discuss how the degeneration of dopaminergic neurons leads to a significant decrease in DA levels, which disrupts motor function. Additionally, they highlight the roles of other neurotransmitters, such as glutamate and GABA, in exacerbating symptoms and contributing to the disease's complexity. The article emphasizes the need for multifaceted therapeutic approaches that target these various neurotransmitter systems to better manage both motor and nonmotor symptoms of PD.
Despite its comprehensive overview, the article acknowledges limitations, including the need for more clinical studies to validate the proposed therapeutic strategies targeting neurotransmitter dysregulation. Patients and caregivers should be aware that while current treatments can manage symptoms, they do not modify the disease's progression. It is essential for individuals with PD to discuss their treatment options and any concerns about neurotransmitter-related symptoms with their healthcare professionals to explore personalized approaches that may improve their quality of life.
Medical Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Aslan Feyza Sule, Barut Beyza, Ozturk Sudenaz, Eyigurbuz Tugba, Akyuz Enes. Neurotransmitter Dysregulation in Parkinson’s Disease: Pathophysiological Insights and Therapeutic Perspectives. ACS Chemical Neuroscience 2026. DOI: 10.1021/acschemneuro.5c00809. PMID: 41904982. PMCID: PMC13088186.
Featured Pill Pals Product
Atomoxetine 60 mg Capsules --- Generic for Strattera --- Glenmark
Atomoxetine 60 mg Capsules — Generic for Strattera — Glenmark is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
